Jasper Therapeutics, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Jeet Mahal (CEO) and Herb Cross (CFO) issued routine Sarbanes-Oxley Section 302 and 906 certifications dated August 14, 2026, attesting to the accuracy of the Q2 2026 10-Q filing and the effectiveness of internal controls and disclosure procedures. No material weaknesses, deficiencies, or fraud are disclosed.
Why this rating
Boilerplate SOX certification. Standard periodic filing requirement; no substantive business, financial, or operational change disclosed.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.